A research collaboration spanning Israel and several European countries has unveiled a breakthrough in cancer treatment that could benefit men with prostate cancer, particularly those with advanced or metastatic disease. Scientists developed biodegradable nanoparticles that deliver two drugs simultaneously, achieving a synergistic effect capable of shrinking tumors more effectively—even at significantly lower doses than usual.

The new nanoparticles tackle this challenge by carrying two FDA-approved drugs within the same “targeting package,” ensuring both agents reach the tumor at the same time. The approach leverages a protein called P-selectin, which is overexpressed on tumor cells and blood vessels, allowing the nanoparticles to “home in” on cancerous tissue while sparing healthy cells.

For some prostate cancer patients, this targeted drug delivery could be particularly impactful. The technology has been shown to penetrate the blood-brain barrier—potentially addressing dangerous brain metastases that can occur in advanced stages of the disease. Early testing in other solid tumors demonstrated improved efficacy, delayed progression, and a survival advantage, all with a reduced risk of side effects thanks to lower drug doses.